Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348462 | 0.85 | ELANE (0.33) | — | |
| SCHEMBL29348405 | 0.82 | MET (0.31) | — | |
| SCHEMBL29348198 | 0.82 | DDB1 (0.45) | F10SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29348199 | 0.82 | DDB1 (0.45) | F10SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29348202 | 0.82 | DDB1 (0.45) | F10SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29348200 | 0.78 | F10 (0.36) | F10SLC6A2SLC6A4SLC6A3PAK1 | |
| SCHEMBL29348769 | 0.78 | F10 (0.36) | F10SLC6A2SLC6A4SLC6A3PAK1 | |
| SCHEMBL29348429 | 0.77 | CNR2 (0.32) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29348458 | 0.77 | CNR2 (0.31) | — | |
| SCHEMBL29348407 | 0.74 | PDCD1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |